Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:51:39 2024-05-23 am EDT			5-day change	1st Jan Change
28.52 ^USD	+2.33%		-2.30%	-1.55%

May. 08	Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	MT
May. 08	Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year of 2022

February 28, 2022 at 04:05 pm EST

Supernus Pharmaceuticals, Inc. provides earnings guidance for the full year of 2022. For the period, the company expects total revenue to be in the range of $640 million and $680 million and operating earnings to be in the range of $20 million and $40 million.

Latest news about Supernus Pharmaceuticals, Inc.

Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	May. 08	MT
Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024	May. 08	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America	May. 07	MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America	May. 07	CI
Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors	Apr. 24	CI
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	Apr. 08	DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	Apr. 08	MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	Apr. 08	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	Mar. 25	MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	Mar. 21	MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM	Mar. 13
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating	Feb. 28	MT
Transcript : Supernus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	Feb. 27	CI
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 27	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	Feb. 27	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Supernus Pharmaceuticals, Inc. Announces Executive Changes	Feb. 21	CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	Feb. 05	MT
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada	Dec. 19	MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada	Dec. 19	MT

Chart Supernus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Sector

Pharmaceuticals

Calendar

04:30pm - R&D Day

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.87 USD

Average target price

40.67 USD

Spread / Average Target

+45.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SUPERNUS PHARMACEUTICALS, INC.	-1.55%	1.53B
KYOWA KIRIN CO. LTD.	+9.28%	8.74B
SK BIOPHARMACEUTICALS CO., LTD.	-14.24%	4.94B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.95%	4.7B
YUHAN CORPORATION	+5.96%	3.98B
BETTA PHARMACEUTICALS CO., LTD.	-23.57%	2.28B
INDIVIOR PLC	+12.07%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+17.77%	2.14B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.28%	2.12B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals